Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT02142491 |
| Other study ID # |
FluMist240713 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
October 25, 2013 |
| Last updated |
May 19, 2014 |
| Start date |
November 2013 |
| Est. completion date |
May 2014 |
Study information
| Verified date |
May 2014 |
| Source |
St. Justine's Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
The objective of this study is to verify the clinical tolerance to the vaccine Flumist
(intranasal live attenuated influenza vaccine) in a population of egg allergic children. More
specifically, the investigators want to estimate the risk of severe allergic reaction arising
within 24 hours following the vaccination of egg allergic with Flumist.
Description:
TITLE: Clinical tolerance of a live, attenuated influenza vaccine (FluMist®) in the context
of influenza immunization in a population of egg-allergic children: A pilot project. Protocol
#: FluMist240713.
1. INTRODUCTION
In Canada, the flu vaccine is indicated for all children between 6 and 23 months of age.
Epidemiologic and clinical studies have demonstrated that these children have a higher
risk of complication and a higher rate of hospitalisation due to influenza. Trivalent
inactivated influenza vaccines (TIV), which are administered intramuscularly, have long
been used for preventative vaccination in this population. FluMist® is a live attenuated
influenza vaccine (LAIV) administrated intranasally, which has been approved for use in
Canada since 2010[1 ]. Besides avoiding the inconvenience and the anxiety related to
intramuscular vaccines, FluMist® offers a better protection against influenza than the
TIV. The Canadian National Advisory Committee on Immunization (NACI) recommends the
preferential use of LAIV over TIV for influenza immunization in children 24 months old
and over. Furthermore, LAIV use is favoured for children with chronic disease and those
suffering from non-severe asthma [ 2].
The influenza vaccine is manufactured using chicken egg embryos and as such, contains
minimal residual quantities of ovalbumin (egg protein). In patients with an egg allergy,
numerous clinical studies have demonstrated that its administration is safe with very
little risk of anaphylactic reaction. Therefore, egg allergy is no longer a
contra-indication to receiving TIV and these patients can now receive this vaccine
without further precautions in CLSCs and doctors' offices[3 ,4 ]. There are no studies
on the safety of LAIV administration in egg-allergic patients. As egg-allergic patients
often have other atopic related comorbidities such as asthma, the increased protection
against influenza which can be achieved with LAIV is desirable. The egg protein content
in LAIV is comparable to that in TIV and its administration is intranasal rather than
systemic. Therefore, it is reasonable to hypothesize that LAIV administration in
egg-allergic patients is as safe as TIV administration in this same population. Yet,
before recommending LAIV in egg-allergic patients, a study on its safety in this
population is essential.
1.1 Use of eggs in the production of influenza vaccines
Because viruses are obligate intracellular parasites, vaccines against viruses must be
produced using human or animal cells. Influenza vaccines currently used in Canada are
produced by allowing the virus to multiply in chicken egg embryos. Despite rigorous
purification processes, these vaccines, including Flumist®, still contain low residual
quantities of ovalbumin (egg protein). The quantity of residual ovalbumin differs, at
times significantly, between the different commercial influenza vaccines available in
Canada, but also between different lots of the same vaccine [3]. While manufacturers
have to assure that the influenza vaccines destined for the Canadian market do not
contain more than 0.24 µg/dose of residual ovalbumin[ ], they are not required to
divulge the final quantity. For this reason, a theoretical risk of anaphylaxis or
hypersensitivity still exists in egg-allergic patients. However, the real risk of an
anaphylactic reaction after an intramuscular influenza vaccination in an egg-allergic
patent is quite low[1].
1.2 Prevalence and clinical presentation of egg allergy
Egg allergy is one of the most common food allergies[6]. Studies have demonstrated that
1 to 2% of young children could be allergic to eggs, which represents approximately 800
children in the 12 to 23 month age group in Quebec[7 ,8]. This allergy is often
diagnosed around 18 months of age, when egg is introduced into the child's diet. Almost
half of egg-allergic children are identified around 10 months of age[9 ,10 ]. We
estimate that this allergy will have completely disappeared by the age of 5 in 66% of
allergic children and 7 years of age in by 75%[11 ,12 ]. In the last decades, the
duration of egg hypersensitivity seems to have increased until late childhood and
sometimes into adolescence[13 ]. Persistent egg allergy into adulthood is rare.
Persistent egg allergy essentially remains a paediatric issue. We can, therefore,
estimate that in Quebec, there are over 3000 egg-allergic children between 1 and 9 years
of age.
The clinical presentation of egg allergy varies significantly. The signs and symptoms of
IgE mediated allergic reactions can touch many systems and can have variable intensity,
ranging from mild to severe. Symptoms can occur within a few minutes to several hours
after ingestion of an egg-containing product, but the majority of allergic reactions
occur within 30 minutes of contact[9]. The incidence of severe allergic reactions
(anaphylaxis) to eggs is rare. We estimate that 7 to 10% of all declared anaphylactic
reactions are due to egg protein[14 ].
2. SAFETY OF VACCINES IN EGG-ALLERGIC PATIENTS
2.1 Safety of the influenza vaccine in egg-allergic patients
In 1976, an outbreak of porcine H1N1 influenza A was observed in American army recruitment
camps in Fort Dix, New Jersey. Despite this outbreak being relatively limited to recruitment
camps, American health authorities implemented, in the general population, a massive
vaccination campaign against this influenza strain. Before being abruptly stopped because of
an increase in the number of cases of Guillain-Barre syndrome, over 48 million people had
been vaccinations against this disease. Jointly to the mass vaccination campaign, the CDC had
implemented a national surveillance program for post-vaccination side effects and had only 11
cases of post vaccination anaphylaxis registered. None of these cases occurred in
egg-allergic patients. However, we are unaware of the number of people vaccinated who had an
egg allergy, which limits the scope of the observed results.
Studies completed thereafter in egg-allergic children tended to demonstrate that this vaccine
could safely be administered. A review of the literature of 27 studies prior to 2012 (table
1) consisting of 4172 egg-allergic patients vaccinated with TVI was published by our
group[3]. Amongst these patients, no cases of severe allergic reactions were observed. The
most common observed allergic reactions were mild (local erythema, local or distal urticaria,
mildly wheezy breathing), though 1 patient did present generalized urticaria.
Since then, some other studies on this subject have been published. More specifically, the
study by Greemhawt et al[15 ] demonstrated via retrospective and prospective cohorts, the
safety of single dose TIV vaccination in severely egg-allergic patients.
Finally, a multicenter study conducted by our group over 5 influenza vaccine seasons
permitted a better estimate of the risk of allergic reaction. Four hundred and fifty-seven
doses of trivalent inactivated influenza vaccine were administered to 367 patients of which
132 (153 doses) reported a severe allergic reaction to eggs[4]. Four patient reported
possible mild reactions secondary to previous influenza vaccines (1 urticaria, 2 vomiting and
1 eczema), but no severe allergic reactions were observed during the study. Thirteen patients
developed mild allergic appearing symptoms in the 24 hours following vaccine administration
but none of the 367 patients developed an anaphylactic reaction. Using a 95% confidence
interval (Clopper-Pearson exact CI), the obtained results of this study allowed us to
estimate a risk of anaphylaxis between 0 and 0.08% (0 to 1 on 1250 doses) for global
population of egg-allergic patients and between 0 to 0.62% (0 to 1 on 161 doses) for patients
with history of severe allergic reaction to eggs.
Following this study, the Quebec immunisation protocol (PIQ) was amended and now permits the
administration of the influenza vaccine in egg-allergic patients in a single dose and in
usual vaccination centers. Since these changes were implemented in the PIQ, no cases of
anaphylaxis or death have been reported in this population.
2.2 Safety of LAIV (Flumist®)
Two formulations of FluMist® have been studied worldwide: a frozen (0.5ml/dose) and a
refrigerated (0.2ml/dose). These 2 formulations are produced from the same viral strains and
have a comparable degree of clinical efficacy. However, only the refrigerated (0.2ml/dose)
formulation is authorised for use in Canada.
FluMist® is composed of attenuated viruses which cannot replicate at the temperature of the
nasal mucosa. The most often reported side effects are nasal congestion and rhinorrhea.
Since people receiving this vaccine can excrete the virus in their nasal secretions in the
days following vaccination, it is recommended to avoid this vaccine in immunocompromised
patients and healthcare workers who are in contact with immunocompromised patients.
Furthermore, it is recommended to avoid this vaccine in patients with severe asthma (defined
as an individual on oral corticosteroid therapy or on high dose inhaled corticosteroids or an
individual with wheezing on auscultation) (see section 3.4) and egg-allergic patients (see
section 3.3).
2.3 Safety of LAIV (Flumist®) in egg-allergic patients: risk associated with a potential
allergen administered intranasally
When the quantity of residual ovalbumine was measured by independent laboratories, only very
low quantities were found, ranging between 0.00013 to 0.0017 µg per 0.2ml dose. The quantity
of egg protein found in the intranasal vaccine is therefore, similar to that found in the
TVI.
Given the different mode of administration between the TIV and the LAIV (intramuscular versus
intranasal), it is important to underline the potentially different absorption of ovalbumin
and its impact on the risk of an allergic reaction. Some studies have analyzed the absorption
and the physiologic response when a food allergen is administered intranasally. More
specifically, Clark et al[16 ] used the method of intranasal peanut provocation in allergic
patients to evaluate the thermographic changes in nasal temperature. In their double-blinded
provocation study, 10 µg of sterilized peanut extract was used for a nasal provocation and
among the 16 patients, none presented systemic symptoms. Taking into account that the
quantity of ovalbumin in LAIV is usually less than 0.24 µg per dose[1], and that the
theoretic dose of food allergen is 40 times higher in the Clark et al study, the risk of an
allergic reaction associated with the administration of LAIV in a egg-allergic population
seems very low.
Moreover, when the systemic absorption of intranasally administered medications is compared
to their oral form, it is much less important[17 ]. Ratner et al[18 ] demonstrated that the
absorption of beclomethasone was approximately four times less than when administered
intranasally. The quantity of ovalbumine which will truly be absorbed is probably
significantly less than 0.24 µg contained in the LAIV.
2.4 Safety of Flumist® in asthmatic patients
Unlike American recommendations which suggest to avoid LAIV in all asthmatic patients[19 ],
the National Advisory Committee on Immunization (NACI) of the Public Health Agency of Canada
(PHAC) recommends this vaccine in asthmatic patients except those with severe asthma defined
as asthmatic individuals on oral corticosteroids or on high dose inhaled corticosteroids or
asthmatic individuals with wheezing on auscultation[4].
Unlike American recommendations, Health Canada recommendations are based on more recent
studies. Many studies have demonstrated the efficacy and the safety of using LAIV in a
population of moderately to severely but stable asthmatic individuals. In 2003, Flemming et
al[20 ] demonstrated in 2000 asthmatic children and adolescents a better efficacy of LAIV as
well as an asthma exacerbation rate similar to TIV. Furthermore, Redding et al[21 ] studied
the safety of LAVI in 1997 with 48 patients between 9 to 17 years old with moderate to severe
but stable asthma. The percentage of change in forced expiratory volume (FEV1) evaluated up
until the fifth day was similar between the vaccinated and the placebo group (0.2% versus
0.4%, p=0.78).
2.5 Intradermic testing with the flu vaccine
Intradermic testing with the flu vaccine does not detect egg-allergic patients who are at
greater risk of developing an allergic reaction after administration of the flu vaccine.
Therefore, its use in not recommended[22 ].
3. AIM
The aim of this study is verify the clinical tolerance of the inactivated, attenuated flu
vaccine (Flumist®) in an egg-allergic population. More specifically, we will estimate the
risk of severe allergic reactions in the 24 hours following vaccination with Flumist® in
egg-allergic patients.
4. METHODS
4.1 Population :
4.1.1 Case group
4.1.1.1 Inclusion criteria
Children between 2 and 17 years of age with a confirmed egg allergy and for whom the flu
vaccine is indicated because they are considered at high risk or because they desire
protection against the flu virus.
4.1.1.2 Confirmation of an egg allergy
Confirmation of an egg allergy requires a set of criteria which vary depending on whether or
not they have ever eaten eggs.
4.1.1.3 Patients having already eaten eggs must meet the following 2 conditions:
1. Patients must have experienced in the 60 minutes following ingestion one of the signs or
symptoms listed below:
Mild sings/symptoms:
1) Cutaneous pruritis or mild urticaria (less than 5 urticarial plaques) or erythema 2)
Rhinorrhea, sneezing or nasal congestion 3) Pruritis, erythema, edema or tearing 4)
Throat or palate pruritis 5) Dyspnea (not objectified) 6) Vomiting or diarrhea
Moderate to severe signs/symptoms:
1. Facial angioedema
2. Systemic urticaria (more than 5 urticarial plaques)
3. Objectified dyspnea or respiratory distress
4. Wheezy breathing
5. Cough
6. Weakness or altered level of consciousness
7. All other reactions requiring administration of epinephrine
2. confirmation of the allergy by one of the following methods within 6 months of the
reaction:
1. a positive egg skin prick test (diameter of induration > 3 mm more than the
negative control (saline) read 10 to 15 minutes after the procedure).
2. a specific egg IgE level >0.35 kIU/L
4.1.1.4 In patients never having consumed eggs or egg containing products or with an
uncertain clinical history of reaction to eggs, the diagnosis must be confirmed by the
following 2 methods in the 6 months following the reaction:
1. a positive egg skin pric test and
2. a specific egg IgE level measured by ImmunoCAP of: > 2kIU/L in children less than 2
years old or > 7kIU/L in children 2 years old and over.
4.1.1.5 Exclusion criteria
We could not vaccinate patients with the following conditions. However, some of these
conditions can be temporary as they are reversible. Therefore, vaccination must be done at a
moment when the situation has improved.
Exclusion criteria:
1. poorly controlled asthma on the day of vaccination defined by the presence of wheezy
breathing and/or cough at the time of vaccination or wheezing on auscultation;
2. severe asthma defined as an individual on oral corticosteroids or on high dose inhaled
corticosteroids;
3. the presence of an urticarial rash on physical exam;
4. the use of antihistamines (first or second generation) 3 to 7 days (respectively) before
vaccination;
5. the presence of a moderate to severe acute illness (with for example, fever,
irritability, inconsolable crying, lethargy, abnormal fatigue, vomiting, diarrhea,
pallor, cyanosis or diaphoresis);
6. immunocompromised patients and healthcare workers in contact with immunocompromised
patients.
4.1.2 Control group
100 individuals without a history of egg allergy, never having received the intranasal flu
vaccine will be recruited. These control subjects will be recruited in a manner to allow a
similar age distribution to the allergic patients.
4.1.2.1 Inclusion criteria
Children between 2 and 17 years of age without a history of egg allergy and for whom there is
an indication for the flu vaccine because they are considered at risk for complications or
because they desire a protection against the flu virus.
4.1.2.2 Exclusion criteria
They are the same as in the case group. See section 4.1.1.5.
4.1.3 Identification of patients
Allergic patients will be contacted starting in October to inform them of this project. This
will include:
1. Known allergic patients who will be contacted by their allergists themselves;
2. Patients of pediatricians and general practitioners who have been informed of the
project and who will have been referred;
3. The department of allergy and immunology will sent to known egg-allergic patients a
letter informing them of the project and inviting them to take an appointment at the
clinic. These patients will be identified by, among other things, lists of positive egg
specific IgE levels done in the last 24 months;
4. As needed, an ad for the project, in written media or electronically, could be used.
Controls will be recruited at the allergy clinic at Ste-Justine hospital. These patients may
be followed for allergies but will not have an egg allergy. Controls may also be recruited by
ads in social media or by other services.
4.2 Clinical procedures
On the vaccination day, participants will have to follow the procedure below:
1. A research nurse will explain to the parents of the participants what is to be expected
in the context of this project. She will ask the patients to read the consent form for
the project. She will mention that there will be a follow-up by telephone 24 hours after
the vaccination to ask about the clinical status of the child. Those who accept will
have to sign the consent form. If they do not accept, they will be vaccinated using TIV
according to the current recommendation of Quebec public health.
2. In the context of the clinical approach of our service, parents will fill out an
auto-administered questionnaire on the clinical history of their child's egg allergy.
This questionnaire will take approximately 15 minutes to complete. The allergist will
verify the answers with the parents and will proceed to examine the child including an
examination of the skin and pulmonary auscultation at most 30 minutes prior to
vaccination. For the control subjects, the physical exam will also be done by the
allergist in the clinic.
3. For children with an egg allergy, a clinical revaluation (skin prick test and egg
specific IgE levels by ImmunoCap) will be done if the latest values are more than 6
months old or if they are not adequately documented. This test will take approximately
15 minutes.
4. The vaccine used will be the live, attenuated influenza vaccine (LAIV) i.e Flumist® by
AstraZeneca. As the egg allergen (ovalbumin) content in LAIV is comparable to the
intramuscularly administered vaccine and that the risk of allergic reaction with TIV has
been shown to be very low when administered in a single dose, the intranasal vaccine
Flumist® will be administered by the nurse or doctor in a single dose of 0.2ml
intranasally, as recommended by the manufacturer. This vaccination will be followed by a
60 minute observation period. We will examine the child 60 minutes after vaccination and
at any time if the child, parent or personnel suspects an allergic reaction or adverse
effect.
The wait time after the vaccination will occur in the waiting room of the allergy clinic
under the supervision of a nurse. We will ask the parents and the child to inform the
doctor or the nurse if they observe any of the following manifestations: erythema,
pruritis, rash, sneezing, rhinorrhea, tearing, nasal congestion, voice change, cough,
difficulty breathing, noisy breathing, pallor, weakness, vomiting or diarrhea. We will
ask them to also advise the members of the research team of any other reactions or
concerning states.
5. Before leaving, parents will be questioned on the presence of allergic symptoms.
If a reaction occurs, it will be treated based on the allergist or supervision doctor
decision. The allergy clinic where vaccination will occur is equipped with the necessary
material to treat an allergic reaction i.e. epinephrine, oral and injectable
diphenhydramine, inhaled salbutamol, oral and intravenous corticosteroids and oxygen.
6. Telephone follow-up
All parents will receive an emergency phone number to contact in case of allergic
reaction within the 24 hours following vaccination. This will be the contact information
of the principal investigator of the project, Dr Anne Des Roches, or the allergist on
call if she is absent. Moreover, the phone number will also be provided to the
telephonists of Ste-Justine Hospital who can call Dr Des Roches or the allergist on
call. She (or he) will evaluate the patient for a biphasic reaction or for a delayed
reaction or could have the patient come to the allergy clinic or refer the patient to
the emergency department according to the situation. Parents will be advised to contact
emergency services first if there is a severe delayed reaction.
Parents will be called the following day to enquire about the presence of any allergic
manifestation that could have appeared in the 24 hours following vaccination.
4.2.1 Second dose
Children between 2 and 8 years of age, who have never received a trivalent seasonal flu
vaccine and who have tolerated the first dose, will be invited to a second appointment
to receive a booster dose, 1 month later. The second dose will be followed by on
observation period of 15 minutes.
4.3 Sample size
As this is a pilot project, we aim to recruit of 100 egg-allergic patients and 100
control patients. According to the results, a multicentre study on a large number of
egg-allergic patients could be done at a later time.
4.4 Primary outcome and statistical analysis
The primary outcome will be the presence of anaphylactic reactions following flu
vaccination with LAIV. An anaphylactic reaction will be defined according to the
Brighton Collaboration criteria, an international organization that standardises the
criteria defining vaccine side effects[23].
Secondary outcomes will be the presence of all allergic manifestations as described in
section 4.1.1.3 within the 24 hours following flu vaccination.
We will compare the proportion of patients and control presenting allergic symptoms
using the exact Fisher test. We will estimate the risk of anaphylaxis and its 95%
confidence interval using the Clopper-Pearson exact method.
4.5 Schedule and surveillance of the study
This study will be conducted over a period of 6 months, i.e. from October 2013 to March
2014, which corresponds to the flu vaccination period.
An analysis of the data pertaining to anaphylactic reaction will be compiled regularly
by the study's principal investigator.
The study will cease if one of the following situations occurs during the study:
- if a child develops fatal or almost fatal reaction;
- if more than 2% of children develop reactions requiring epinephrine administration.
5. Risks and benefits of the study
For egg-allergic patients who desire the flu vaccine, the risk of participation in this
study is the risk of developing an allergic reaction following Flumist® vaccination.
Although nasal congestion, rhinorrhea and cough are the most common reported side
effects in patients receiving this vaccine, if an allergic reaction occurs, it could
manifest as more important nasal symptoms (congestion, rhinorrhea, pruritis, sneezing,
edema), as well as oral symptoms or systemic symptoms, accompanied by pruritis,
urticaria, wheezy breathing or, in severe cases, hypotension, throat swelling or
tightness and/or difficulty breathing. An allergic reaction can also present as nausea,
abdominal pain and/or sudden vomiting. Patients will be monitored closely during the
whole procedure, as well as in the hour following it for the onset of these symptoms. If
need be, they will be seen by the study doctor who will evaluate the need for
antihistamines, epinephrine, corticosteroids or who will institute specialized
techniques to maintain vital functions. The risk of a severe reaction is probably very
low considering the low egg content in the vaccine.
For the control group, there is no additional medical risk to participating in this
study, as they will be receiving the seasonal flu vaccine in the same manner that they
would if they were not participating in the study and no supplemental procedure will be
necessary except for an observation period of 60 minutes, a follow-up telephone call 24
hours after vaccination and a short medical questionnaire.
Aside from a more stringent observation for reactions to the vaccine, controls will not
encounter any direct benefits to their participation in this study. For the case
participants, the intranasal flu vaccine will allow them to obtain a better protection
against the seasonal flu vaccine than received with TIV.
Furthermore, if the results obtained confirm the safety of FluMist® in egg-allergic
patients, this will allow reassurance of healthcare professional of the safety of
vaccination in egg-allergic patients. More long term, this will allow egg-allergic
patients to receive the LAIV rather than being limited to TIV.
6. Medications under investigation The FluMist® vaccine made by AstraZeneca will be
provided and routed to Ste-Justine Hospital by the National Institute of Public Health
under the specific storage conditions set by the manufacturer. The vaccines will be
under the conditions required by the manufacturer in the Ste-Justine research center,
under the responsibility of the principal investigator. The Ste-Justine research center
is equipped with a refrigerator with temperature control monitors, allowing for
verification of all changes in temperature which can then be reported to the principal
investigator. Vaccines will be stored in a safe and secure environment. Information
pertaining to the arrival of the vaccines, the doses administered and the return or
destruction (if warranted) of the vaccines will be documented.
7. Protection of data
The data compiled from this study will be anonymized and entered into an Excel database.
The database will be kept on a Ste-Justine computer which can only be accessed by the
research team. The computer is username and password protected and is situated in a
locked office.
8. Adverse reactions to medication report In this study, Canadian regulations will apply
for the reporting of serious adverse effects. For medications used in the context of
clinical trials in Canada, only serious and unexpected adverse effects must be rapidly
reported to Health Canada.
Serious but expected adverse effects and serious therapeutic incidents observed during
the clinical trial but not considered secondary to the product in question, whether they
are expected or not, do not require expedited reporting.
A report will be completed in the following cases:
- in the 15 days following the moment when the situation if known, if the effect is not
fatal but puts the patient's life in danger;
- as soon as possible in the 7 days following the moment when the situation if known, if
death occurs or if the effect can put the patient's life in danger;
- in the 8 days following the notification of Health Canada of adverse effects, a
detailed report containing an estimation of the importance of the repercussions and
findings.
Each case of adverse effects subject to expedited declaration will undergo a distinct
declaration consisting of the all the elements required in Health Canada guidelines/ICH
E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.
Data pertaining to the harmlessness of a medication will be communicated in an ongoing
process to the research ethics committee.
9. Surveillance of data security committee
A committee to monitor the security of the collected data shall be formed by
professionals who are not implicated in the elaboration of this protocol. The
regulations set out by Health Canada shall be followed.
The primary responsibilities of this committee shall be the following:
1. Periodic meetings (approximately every 2 months or more if necessary) to evaluate
the study results in respect to security, the management of the study and the
progress of recruitment.
2. To elaborate recommendations on the continuation, modification or cessation of the
study.
3. To evaluation compiled serious adverse effects.
10. Ethics Parents who do not wish to sign the consent form can get their children
vaccinated with TIV according to the regular clinical protocol as recommended by Quebec
public health.
The information and consent forms will explain to the control group that they must
remain in the clinic for a longer period of time after vaccination then would be
normally required (60 versus 15 minutes) and that they will have to fill out a short
medical questionnaire as well as receive a follow-up phone call.
The safety of patients will be assured by providing vaccination in a center equipped
with all the necessary material and personnel to rapidly respond to an anaphylactic
reaction, rapid access to an emergency department and close observation.
Questionnaire will only identified by number and only this number will be used in the
database to ensure confidentiality.
11. Schedule
June 2013 Submission to the ethics committee
30 October 2013 Start of vaccination
12. References: Available upon request
